Hana Pharm Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 1.34%

Hana Pharm Co Ltd (293480) has an Asset Resilience Ratio of 1.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Hana Pharm Co Ltd carry for a breakdown of total debt and financial obligations.

Liquid Assets

₩5.43 Billion
≈ $3.68 Million USD Cash + Short-term Investments

Total Assets

₩405.15 Billion
≈ $274.57 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how Hana Pharm Co Ltd's Asset Resilience Ratio has changed over time. See Hana Pharm Co Ltd book value and equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hana Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hana Pharm Co Ltd stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩5.43 Billion 1.34%
Total Liquid Assets ₩5.43 Billion 1.34%

Asset Resilience Insights

  • Limited Liquidity: Hana Pharm Co Ltd maintains only 1.34% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Hana Pharm Co Ltd Industry Peers by Asset Resilience Ratio

Compare Hana Pharm Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Hana Pharm Co Ltd (2016–2024)

The table below shows the annual Asset Resilience Ratio data for Hana Pharm Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.95% ₩3.64 Billion
≈ $2.47 Million
₩382.01 Billion
≈ $258.88 Million
-0.41pp
2023-12-31 1.36% ₩4.73 Billion
≈ $3.21 Million
₩348.39 Billion
≈ $236.10 Million
-0.10pp
2022-12-31 1.46% ₩5.03 Billion
≈ $3.41 Million
₩345.96 Billion
≈ $234.46 Million
-15.10pp
2021-12-31 16.56% ₩50.25 Billion
≈ $34.05 Million
₩303.50 Billion
≈ $205.68 Million
-2.54pp
2020-12-31 19.10% ₩52.83 Billion
≈ $35.80 Million
₩276.58 Billion
≈ $187.43 Million
-9.19pp
2019-12-31 28.29% ₩74.42 Billion
≈ $50.44 Million
₩263.03 Billion
≈ $178.25 Million
-8.56pp
2018-12-31 36.85% ₩89.32 Billion
≈ $60.53 Million
₩242.38 Billion
≈ $164.26 Million
+34.34pp
2017-12-31 2.51% ₩3.55 Billion
≈ $2.41 Million
₩141.55 Billion
≈ $95.93 Million
+0.96pp
2016-12-31 1.54% ₩1.77 Billion
≈ $1.20 Million
₩114.59 Billion
≈ $77.66 Million
--
pp = percentage points

About Hana Pharm Co Ltd

KO:293480 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$115.01 Million
₩169.71 Billion KRW
Market Cap Rank
#18657 Global
#964 in Korea
Share Price
₩9810.00
Change (1 day)
-1.11%
52-Week Range
₩9090.00 - ₩12430.00
All Time High
₩26028.86
About

Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more